ORIGINAL ARTICLE
CHADS2 Score as a Predictor of Acute kidney Injury in Diabetic Patient Undergoing Elective Coronary Intervention

Tarek Said Zolfakar, Nader Talaat Kandil, Alaa El-Sayed Salama, Ahmed Mohamed Saad*

1Cardiology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

*Corresponding Author:
Ahmed Mohamed Saad
Cardiology Department, Faculty of Medicine, Zagazig University, Egypt.
dr.ahmedsaad45@gmail.com

ABSTRACT
Background: one of major adverse outcome of cardiac catheterization is acute kidney injury (AKI), and is associated with short-term and long-term mortality and morbidity. The pathogenesis of AKI is still not established although it is thought that the mechanism is medullary hypoxia lead to renal tubular dysfunction. Objective: The aim of the study is to assess the efficacy of CHADS2 score in prediction of AKI in diabetic patients after percutaneous coronary intervention (PCI).

Methods: This study was prospective cohort study done on 60 patients have diabetic history divided into two groups according to incidence of AKI. All diabetic patients underwent elective PCI. All patients had the following: complete blood count, renal function, glycosylated hemoglobin (HbA1C), Resting electrocardiography, echocardiography Doppler study. Serum creatinine was assessed before intervention, 48 hours after exposure to contrast media in PCI. Creatinine clearance was assessed also before and 48 hours after the intervention.

Results: AKI developed in eight patients (13.3%) one patient with CHADS2 score < 3 and 7 patients have CHADS2 score > 3. The result showed that CHADS2 score is an independent predictor for incidence of AKI [odds ratio (OR) =8.111; 95% confidence interval (C.I) = 1.096 – 60.011; p=0.04]. There was a significant increase in AKI incidence with increased CHADS2 score.

Conclusions: CHADS2 score is more accurate and sensitive in diagnosis of acute kidney injury after coronary intervention in comparison with old complicated scoring system.

Key words: (acute kidney injury, CHADS2, coronary intervention)

INTRODUCTION
One of major adverse outcome of cardiac catheterization is acute kidney injury (1). The reported incidence of AKI is widely varies in different populations, the ranking of AKI from 7% to 25%, depending mainly on the presence of risk factors (2, 3).

It's associated with increased in-hospital and long-term mortality and morbidity, prolonged hospital stay, and long-term renal dysfunction (1) so, risk stratification is very important to apply the appropriate extent of prophylactic strategy in suspected high-risk populations.
In general, many models have been proposed to predict the incidence of AKI. In 2004, Mehran (4) reported a scoring system containing 8 variables, with fair correlation to the risk of AKI. In 2013, Gurm (5) created other model containing 15 variables with better discrimination of AKI incidence than Mehran’s score. Although the accuracy of this scoring systems it is limited by their complexity and require various examinations to complete the risk stratification.

CHADS2 score is used for risk stratification of embolic events in patient's complaining atrial fibrillation. The components of The CHADS2 score, such as diabetes, age and heart failure, have also been reported also as risk factors for AKI and adverse cardiac events. Recently the CHADS2 score helps to identify patients with poor outcome in acute myocardial infarction (6) However, information about the usage of the CHADS2 score in predicting AKI is limited.

We conducted this prospective cohort study to determine the correlation between CHADS2 score and risk of AKI in patients with diabetic disease underwent elective PCI.

The aim of our study was to assess the efficacy of CHADS2 in prediction of AKI in diabetic disease patients with normal serum creatinine after elective coronary intervention.

**METHODS**

Written informed consent was obtained from all participants and the study was approved by the research ethical committee of Faculty of Medicine, Zagazig University. The work has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for studies involving humans.

Our study was a prospective cohort study carried on cardiology department of Zagazig University during the period from October 2015 to December 2018 included 60 randomly selected patients who were admitted to our coronary care unit for elective coronary intervention divided into two groups:

- No AKI group included 52 patients.
- AKI group included 8 patients.

**Inclusion criteria** Diabetic patient undergo elective coronary angiography, classified according to incidence of AKI.

**Exclusion criteria:**
- Patients were excluded from the study if one or more of the following criteria were present
- Patients with chronic renal disease.
- Patient with acute myocardial infarction.
- Patient with atrial fibrillation.
- Patients with malignancies.

All patients underwent the following:

1. **Complete history taking:** Including age, sex, smoking, hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease and other medical conditions.

2. **Full clinical examination and cardiac assessment:** Heart rate, blood pressure, cardiac auscultation and peripheral Pulsation.

3. **Electrocardiogram (ECG):** A 12-lead surface ECG was done for each patient on admission for diagnosis of ischemic changes or exclude new changed and STEMI.

4. **Doppler – echocardiography:** for assessment of LV function by M-mode, regional wall motion abnormality.

5. **Laboratory investigations:** complete blood count (CBC) and random blood sugar and kidney function (serum urea, serum creatinine, creatinine clearance) before and after coronary intervention and glycosylated hemoglobin (HbA1C%).

6. **Calculating CHADS2 score:** Ages >75 years (1), HTN (1), DM (1), Heart failure (1), Previous stroke or TIA (2).

7. **Percutaneous coronary intervention.**

**Swatistical Analysis**

Data were analyzed using Statistical Program for Social Science (SPSS) version 23. Quantitative data were expressed as mean ± standard deviation (SD). Qualitative data were expressed as frequency and percentage.

We use the following tests of significance: Independent-samples t-test, Mann Whitney U test, Chi-square (X2) test, Fisher Exact test and Wilcoxon Signed-Ranks Test. Receiver
operating characteristic (ROC) curve analysis was used to identify optimal cut-off values. Sensitivity, specificity, PPV (positive predictive value), NPV (negative predictive value) was used to plot Receiver Operating Curve (ROC). Statistical significance was assessed at P values less than 0.05.

RESULTS

Demographic data of the studied groups
Regarding the age, in no AKI group the age ranged from 39 to 78 years with mean 60 ± 10.4 years, in AKI group the age ranged from 55 to 78 years with mean value 68.3 ± 9.6 years. The main difference between the two groups was statistically non-significant (P =0.055).

Regarding gender, no AKI group there were 34 males (65.4 %) and 18 females (34.6 %), AKI group there were 6 males (75 %) and 2 females (25%). There was a non-statistically significant difference between the two groups with (P-value=0.707).

Regarding body weight, no AKI group the body weight range from 64 to 115 with mean 86.8 ± 11.9 in AKI group the body weight range from 75 to 90 with mean 83.3 ± 6.4. There was a non-statistically significant difference between the two groups with (P-value=0.416).

Regarding smoking, no AKI group there were 20 (38.5%) smoking patient while in AKI group there were two (25%) smoking patient. There was a non-statistically significant difference between the two groups with (P-value=0.698). (Table1)

The cardiovascular risk factors (CHADS2 score) in each group
Regarding hypertension, no AKI group there were 32 patients hypertensive (61.5%) while in AKI group there were 8 patients hypertensive (100%). There was a statistically significant difference between the two groups with (P-value=0.043).

Regarding diabetes mellitus, no AKI group there were 52 patients diabetic (100%) while AKI group there were 8 patients diabetic (100%) there was a non-statistically significant difference between the two groups with (P-value=0.631).

ECG findings of the studied groups
Regarding ECG, in no AKI group there were 5 patients (9.6%) had no ECG changes, 26 patients (50%) had anterior wall ischemia, 8 patients (15.4%) had lateral wall ischemia and 13 patients (25%) had inferior wall ischemia. While in AKI group there were 0 patients (0%) had no ECG changes, 2 patients (25%) had anterior wall ischemia, 1 patient (12.5%) had lateral wall ischemia and 5 patients (62.5%) had inferior wall ischemia. (Table3)

Abdominal sonographic and echocardiographic data findings of the groups
Regarding Abdominal U/S, in no AKI group there were 43 patients (82.7%) had normal U/s while 9 patients (17.3%) had Nephropathy (I) while in AKI group there were 6 patients (75%) had normal U/s while 2 patients (25%) had Nephropathy (I).

There was a non-statistically significant difference between the two groups with (P-value=0.631).

Regarding echocardiography, in no AKI group the EF ranged from 35 to 72 % with mean 58.4
± 9.4, in AKI group the EF ranged from 35 to 60 % with mean value 51.4 ± 8.6.
The main difference between the two groups was statistically non- significant (P =0.141) (Table4)

**Laboratory findings of the studied groups**

**Regarding serum creatinine Before PCI:**
- In-group I the level of creatinine ranged from 0.65 to 1.5 mg/dl with mean 1.02 ± 0.25.
- In-group II the level of creatinine ranged from 0.7 to 1.3 mg/dl with mean value 1.01 ± 0.20.
The main difference between the two groups was statistically non-significant (P = 0.141) (Table4)

**Laboratory findings of the studied groups**

**Regarding serum creatinine after PCI:**
- In-group I the level of creatinine from 0.7 to 1.62 mg/dl with mean 1.07 ± 0.27.
- In-group II the level of creatinine ranged from 1.4 to 3.7 mg/dl with mean value 2.21 ± 0.69.
The main difference between the two groups was statistically highly significant (P < 0.001).

The main difference between creatinine level before and after PCI in no AKI group was statistically highly significant (p<0.001).

**Laboratory findings of the studied groups**

**Regarding creatinine clearance Before PCI:**
- In-group I the level of creatinine clearance ranged from 52 to 155 ml/min with mean 95.4 ± 31.2.
- In-group II the level of creatinine clearance ranged from 51 to 154 ml/min with mean value 87.5 ± 32.8.
The main difference between the two groups was statistically non-significant (P = 0.579).

**Laboratory findings of the studied groups**

**Regarding creatinine clearance after PCI:**
- In no AKI group the level of creatinine clearance ranged from 48 to 155 ml/min with mean 91.8 ± 31.5.
- In AKI group, the level of creatinine clearance ranged from 24 to 77 ml/min with mean value 41.1 ± 17.3.
The main difference between the two groups was statistically highly significant (P < 0.001).

The main difference between creatinine clearance before and after PCI in no AKI group was statistically highly significant (p<0.001).

In addition, the main difference between creatinine clearance before and after PCI in AKI group was statistically significant (p=0.012).

**Regarding HBA1c:**
- In no AKI group, HBA1c ranged from 6.9 to 9.7 % with mean 7.54 ± 0.50.
- In AKI group, HBA1c ranged from 7.8 to 9.2 % with mean value 8.36 ± 0.52.
The main difference between the two groups was statistically highly significant (P <0.001). (Table5)

**PCI data of the studied groups**

Regarding contrast volume (ml), in no AKI group the volume ranged from 125 to 375 ml with mean 233.2 ± 64.3, while in AKI group the volume ranged from 250 to 400 ml with mean value 331.3 ± 49.6.
The main difference between the two groups was statistically significant (P <=0.001).

Regarding radiation time (min), in no AKI group the time ranged from 20 to 60 min with mean 31.0 ± 10.1, while in AKI group the time ranged from 35 to 65 min with mean value 43.1 ± 10.3.
The main difference between the two groups was statistically significant (P =0.003).

Regarding number of vessels, no AKI group there were 38 patients with one vessel lesion (73.1%) and 11 patients with two vessel lesion(21.1%) and 3 patients with three vessel lesion(5.8%).

While in AKI group, there were two patients with one vessel lesion (25%) and six patients with two-vessel lesion (75%) and no patient with three-vessel lesion (0%).

There was a statistically significant difference between the two groups with (P-value=0.007). (Table6)

**Logistic regression analysis for CHADS2 score to AKI**

There is an increase of one point in the CHADS2 score is associated with a 573.8% significant increase the incidence of AKI [odds ratio (OR) =6.738; 95% confidence interval (C.I) = 2.027 - 22.399; p=0.002]. (Table7)

**Multiple logistic regression analysis for different**
A multivariate logistic regression model was performed to ascertain the effects of CHADS2 score, radiation time, contrast volume and age on the likelihood that participants would have AKI. The result showed that CHADS2 score is an independent predictor for incidence of AKI (odds ratio (OR) = 8.111; 95% confidence interval (C.I) = 1.096 – 60.011; p=0.04). (Table 8)

ROC curve analysis regarding AKI

ROC curve analysis was done to pick up the best cut off value of CHADS2 risk scores and incidence of AKI which revealed CHADS2 risk score more than 3 with sensitivity 62.5% and specificity 96.2% Area under the curve 0.895 (P-value <0.001). (Table 9) (Figure 1)

**Table 1. Comparison between the studied groups regarding demographic data.**

<table>
<thead>
<tr>
<th>Demographic data</th>
<th>No AKI</th>
<th>AKI</th>
<th>Fisher’s Exact test</th>
<th>p-value (Sig.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count (%)</td>
<td>52 (86.7%)</td>
<td>8 (13.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>34 (65.4%)</td>
<td>6 (75%)</td>
<td>0.288 F</td>
<td>0.707 (NS)</td>
</tr>
<tr>
<td>Female</td>
<td>18 (34.6%)</td>
<td>2 (25%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td>-1.917 *</td>
<td>0.055 (NS)</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>60 ± 10.4</td>
<td>68.3 ± 9.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (Range)</td>
<td>60 (39 – 78)</td>
<td>71 (55 – 78)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight (kg)</td>
<td></td>
<td></td>
<td>0.819 *</td>
<td>0.416 (NS)</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>86.8 ± 11.9</td>
<td>83.3 ± 6.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (Range)</td>
<td>90 (64 – 115)</td>
<td>83.5 (75 – 90)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td>0.541 F</td>
<td>0.698 (NS)</td>
</tr>
<tr>
<td></td>
<td>20 (38.5%)</td>
<td>2 (25%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Independent samples Student's t-test.
• Mann Whitney U test& ‡ Chi-square test.
F Fisher’s Exact test & p< 0.05 is significant. Sig.: significance.
Table 2. Comparison between the patients with AKI and patients without AKI regarding demographic data.

<table>
<thead>
<tr>
<th>Demographic data</th>
<th>No AKI</th>
<th>AKI</th>
<th>Fisher’s Exact test</th>
<th>p-value (Sig.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count (%)</td>
<td>52 (86.7%)</td>
<td>8 (13.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>42 (80.8%)</td>
<td>7 (87.5%)</td>
<td>0.210 †</td>
<td>1.00 (NS)</td>
</tr>
<tr>
<td>CHF</td>
<td>11 (21.2%)</td>
<td>2 (25%)</td>
<td>0.06 †</td>
<td>1.00 (NS)</td>
</tr>
<tr>
<td>HTN</td>
<td>32 (61.5%)</td>
<td>8 (100%)</td>
<td>4.615 †</td>
<td>0.043 (S)</td>
</tr>
<tr>
<td>Age ≥ 75 years</td>
<td>8 (15.4%)</td>
<td>4 (50%)</td>
<td>5.192 †</td>
<td>0.043 (S)</td>
</tr>
<tr>
<td>DM</td>
<td>52 (100%)</td>
<td>8 (100%)</td>
<td>&lt;0.001 ‡</td>
<td>1.00 (NS)</td>
</tr>
<tr>
<td>History of stroke</td>
<td>1 (1.9%)</td>
<td>5 (62.5%)</td>
<td>28.27 †</td>
<td>&lt;0.001 (HS)</td>
</tr>
<tr>
<td>CHADS₂ score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>2.02 ± 0.83</td>
<td>4.00 ± 1.31</td>
<td>-3.755 •</td>
<td>&lt;0.001 (HS)</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>2 (1 – 4)</td>
<td>4 (2 – 6)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* p< 0.05 is significant. Sig.: significance.

Table 3 Comparison between the patients with AKI and patients without AKI regarding ECG.

<table>
<thead>
<tr>
<th>ECG</th>
<th>No AKI</th>
<th>AKI</th>
<th>Fisher’s Exact test</th>
<th>p-value (Sig.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count (%)</td>
<td>52 (86.7%)</td>
<td>8 (13.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>5 (9.6%)</td>
<td>0 (0%)</td>
<td>4.986 ‡</td>
<td>0.173 (NS)</td>
</tr>
<tr>
<td>Anterior changes</td>
<td>26 (50%)</td>
<td>2 (25%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inferior changes</td>
<td>13 (25%)</td>
<td>5 (62.5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lateral changes</td>
<td>8 (15.4%)</td>
<td>1 (12.5%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* p< 0.05 is significant. Sig.: significance.
Table 4. Comparison between the patients with AKI and patients without AKI regarding abdominal sonographic and echocardiographic data.

<table>
<thead>
<tr>
<th>U/S and echo</th>
<th>No AKI</th>
<th>AKI</th>
<th>Fisher’s Exact test</th>
<th>p-value (Sig.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count (%)</td>
<td>52 (86.7%)</td>
<td>8 (13.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Abdominal U/S</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>43 (82.7%)</td>
<td>6 (75%)</td>
<td>0.274 *</td>
<td>0.631 (NS)</td>
</tr>
<tr>
<td>Nephropathy (I)</td>
<td>9 (17.3%)</td>
<td>2 (25%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EF (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>55.4 ± 9.4</td>
<td>51.4 ± 8.6</td>
<td>1.474 •</td>
<td>0.141 (NS)</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>57.5 (35 – 72)</td>
<td>53.5 (35 – 60)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

p< 0.05 is significant. Sig.: significance.

Table 5. Comparison between the patients with AKI and patients without AKI regarding the laboratory data.

<table>
<thead>
<tr>
<th>Laboratory data</th>
<th>No AKI</th>
<th>AKI</th>
<th>Fisher’s Exact test</th>
<th>p-value (Sig.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count (%)</td>
<td>52 (86.7%)</td>
<td>8 (13.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Serum creatinine (mg/dl)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Before PCI</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ±SD</td>
<td>1.02 ± 0.25</td>
<td>1.01 ± 0.20</td>
<td>0.066 •</td>
<td>0.948 (NS)</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>1.0 (0.65 – 1.5)</td>
<td>0.95 (0.7 – 1.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>After PCI</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ±SD</td>
<td>1.07 ± 0.27</td>
<td>2.21 ± 0.69</td>
<td>-4.369 •</td>
<td>&lt;0.001 (HS)</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>1.05 (0.7 – 1.62)</td>
<td>2.15 (1.4 – 3.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test</td>
<td>-4.747 w</td>
<td>-2.527 w</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-value (Sig.)</td>
<td>&lt;0.001 (HS)</td>
<td>0.012 (S)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Creatinine clearance (mL/min)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Before PCI</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ±SD</td>
<td>95.4 ± 31.2</td>
<td>87.5 ± 32.8</td>
<td>0.555 •</td>
<td>0.579 (NS)</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>84.5 (52 – 155)</td>
<td>86.5 (51 – 154)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>After PCI</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ±SD</td>
<td>91.8 ± 31.5</td>
<td>41.1 ± 17.3</td>
<td>3.959 •</td>
<td>&lt;0.001 (HS)</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>81 (48 – 155)</td>
<td>37.5 (24 – 77)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test</td>
<td>4.675 w</td>
<td>2.521 w</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-value (Sig.)</td>
<td>&lt;0.001 (HS)</td>
<td>0.012 (S)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **HbA1c (%)**        |          |        |                     |                |
| Mean ±SD             | 7.54 ± 0.50 | 8.36 ± 0.52  | -3.775 •          | <0.001 (HS)    |
| Median (Range)       | 7.4 (6.9 – 9.7) | 8.2 (7.8 – 9.2) |           |                |

p< 0.05 is significant. Sig.: significance.
Table 6. Comparison between the patients with AKI and patients without AKI regarding PCI data.

<table>
<thead>
<tr>
<th>PCI data</th>
<th>No AKI</th>
<th>AKI</th>
<th>Fisher’s Exact test</th>
<th>p-value (Sig.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count (%)</td>
<td>52 (86.7%)</td>
<td>8 (13.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contrast volume (mL)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ±SD</td>
<td>233.2 ± 64.3</td>
<td>331.3 ± 49.6</td>
<td>3.448•</td>
<td>0.001 (S)</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>225 (125 – 375)</td>
<td>337.5 (250 – 400)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Radiation time (min)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ±SD</td>
<td>31.0 ± 10.1</td>
<td>43.1 ± 10.3</td>
<td>-2.972 •</td>
<td>0.003 (S)</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>30 (20 – 60)</td>
<td>40 (35 – 65)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>N. of vessels</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>One vessel</td>
<td>38 (73.1%)</td>
<td>2 (25%)</td>
<td>9.960 ‡</td>
<td>0.007 (S)</td>
</tr>
<tr>
<td>Two vessels</td>
<td>11 (21.1%)</td>
<td>6 (75%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Three vessels</td>
<td>3 (5.8%)</td>
<td>0 (0%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

p< 0.05 is significant. Sig.: significance.

DISCUSSION
The progress of imaging methods and interventional procedures require administration of contrast media in cardiac modalities (e.g., coronary angiography and PCI) and emerging cardiac modalities (e.g., CT coronary angiography and trans catheter aortic valve implantation (TAVI)) has increased the number of patients exposed to contrast media and increase the risk of AKI(7).

AKI is associated with a marked increase in mortality and morbidity rates (8).

Despite technological advances, AKI incidence remains responsible for about third of all hospital-acquired acute kidney dysfunction (9), and affects between 1% and 2% of the general population and up to 50%
of high-risk groups following both coronary angiography and percutaneous coronary intervention (10).

Identification of patients at increased risk for AKI is challenging. Although the mechanisms of AKI is not fully understood, researchers concluded that AKI is caused by renal vasoconstriction, endothelium cell damage, endothelial dysfunction, followed by medullary hypoxia and renal tubular injury (11). Advanced age, diabetes mellitus, female gender, renal dysfunction and CHF, (12) are already well-known risk factors for AKI. Even high central pulse pressure and hypertension have been reported to be linked to AKI development (13).

The components of the CHA2DS2-VASC and CHADS2 score include similar risk factors for AKI (10). The CHADS2 score was initially developed for stratification of stroke risk in patients with AF is also a convenient scoring system for detecting the complexity of comorbidities in patients with known cardiovascular diseases (14).

There is limited data about the value of the CHADS2 score in the incidence of AKI after patients undergo PCI, but the components of the CHADS2 score are risk factors for development of AKI (4).

The aim of our study was to assess whether the CHADS2 score provide potentially valuable prognostic information's on incidence of AKI.

Our study was conducted on 60 diabetic patients with normal serum creatinine undergoing elective PCI divided into two groups according to incidence of AKI.

Serum creatinine was assessed before and after (within 48 hours) contrast media exposure in the elective PCI.

**Demographic data:**

In our study conducted on 60 patients with mean age 61.1 ± 10.6 years and mean body weight 86.3 ± 11.3kg divided into:

- No AKI group the mean age was 60 ± 10.4 years.
- AKI group the mean age was 68.3 ± 9.6 years.

There was no statistically significant difference between both groups (p=0.055). This was in disagreement with Puurunen et al.,(15) who found that there was a highly statistically significant difference regarding Age (p <0.001).

According to sex our study included 60 patients 20 (33.3%) female and 40 (66.6%) male divided into:

- Group I 18 female (34.6%) and 34 male (65.4%).
- Group II 2 female (25%) and 6 male (75%).

There was no significant difference between both groups (p=0.707) regarding sex. This was in disagreement with James et al.,(16) which examine the association between AKI following coronary angiography, they found that males were 69.9% in the low risk CHADS2 group compared to 57.7% in high risk group (p=0.007).

**Clinical data and risk factors:**

In our study, there was a statistical significant difference regarding hypertension (32 patients in group I and 8 patients in group II) , history of stroke (5 patients in group II with one patient in group I) and Congestive heart failure (11 patients in group I and 2 patients in group II) between the two groups which was concordant with Chou et al., (17), in which 539 patient underwent coronary angiography and intervention divided according to CHADS2 score, While there was no statistically significant difference concerning diabetes between both groups and this was against the result of Chou et al., (17).

Regarding to serum creatinine:

- Before PCI:
It was 1.02 ± 0.25mg/dl Group I while in Group II it was 1.01 ± 0.20mg /dl with no statistically significant difference between both groups which was concordant with (shukla AN et al, (18) in which , 253 patients underwent coronary angiography and/or percutaneous coronary intervention and stated that the mean serum creatinine rise was non-significant.

- 48 hours after PCI:
  It was 1.07 ± 0.27mg /dl in group I and 2.21 ± 0.69mg /dl in group II with statistically significant difference between both groups which was concordant with Chou et al (17).
  In both group I and group II there was highly statistical significant difference between levels of serum creatinine after PCI.
  Although all patients were diabetic but there was a statistical significant difference between both groups regarding HbA1C.
  There was no statistically significant difference between both groups regarding dyslipidemia and smoking which was concordant with Ashalatha et al, (19).
  There was statistically significant difference between both groups regarding the mean volume of contrast media, radiation time and angiographic findings.
  In our study, increased mean volume of CM in PCI was associated with higher incidence of AKI which was concordant with the study of Marenzi et al., (20) which assessed the association between the contrast volume and the incidence of AKI in 561 patients with STEMI underwent Primary PCI.
  The incidence of AKI was 13.3% (8 patients) which was in agreement with Merenzi et al., (7) in which 208 patients presented with acute myocardial infarction underwent Primary PCI the incidence of AKI was 19%, and discordant with Shacham et al.,(21) in which the incidence of AKI was 6.2%.

In our study, CHADS2 score > 3 is a predictor for the incidence of AKI with sensitivity 62.5%, specificity of 96.2% and accuracy of 91.7%.

**CONCLUSION**

CHADS2 score is highly sensitive in diagnosis of acute kidney injury after coronary intervention in diabetic patients rather than old scoring system.

**Limitations of the study**

1-Relatively small sample size of this study.
2-The results were obtained from only two centers.

**RECOMMENDATION**

This study recommends using CHADS2 as a diagnostic tool for acute kidney injury in patients undergoing elective PCI.

**Declaration of interest**

The authors report no conflicts of interest.

The authors alone are responsible for the content and writing of the paper.

**Funding information:** None declared

**REFERENCES**


patients undergoing coronary angiography: a randomized trial. *Jama*, 300(9), pp.1038-1046.


**To Cite This Article:** Tarek SZ., Nader TK, Alaa ES, Ahmed MS. CHADS2 Score as a Predictor of Acute kidney Injury in Diabetic Patient Undergoing Elective Coronary Intervention. ZUMJ 2020;26(1);75-86.DOi: 10.21608/zumj.2019.12188.1213